News | March 13, 2021
Lupin launches authorized generic version of Alinia
Nitazoxanide Tablets, 500 mg (RLD: Alinia) had estimated annual sales of USD 56 million in the U.S.
Nitazoxanide Tablets, 500 mg (RLD: Alinia) had estimated annual sales of USD 56 million in the U.S.
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Intrarosa will not only expand and strengthen our product portfolio into Women's Health in Canada but will cater to satisfy the unmet medical needs.
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Candid Powder brand is a market-leader in its category, with a market share of 64% in the medicated powder category.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Subscribe To Our Newsletter & Stay Updated
